{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:50:23Z","timestamp":1790787023522,"version":"4.1.0"},"reference-count":26,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitor (CPI) therapies are associated with multi-organ immune-related adverse events. Although colonic mucosal changes have been described, inflammatory changes incited by CPIs in the upper gastrointestinal tract have not been well characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To investigate morphologic and immunologic changes incited by CPI therapy in the upper gastrointestinal tract.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>We compared the morphology and immune cell phenotype of gastric and duodenal biopsies from patients treated with anti\u2013cytotoxic T-lymphocyte associated protein 4 (CTLA-4) or anti\u2013programmed death receptor-1\/programmed death ligand-1 (PD-1\/PD-L1) antibodies with biopsies from patients with Helicobacter pylori gastritis, patients with celiac disease, and normal controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Gastric biopsies from patients on CPIs showed chronic gastritis mimicking H pylori gastritis. However, CPI gastritis demonstrated greater numbers of CD8+ intraepithelial lymphocytes, less lamina propria inflammation, fewer plasma cells and CD20+ B cells, fewer lymphoid aggregates, and reduced CD4:CD8 ratio in both the lamina propria and the epithelial layer. There were no differences between anti\u2013CTLA-4 and anti\u2013PD-1\/PD-L1 gastritis, except for more lymphoid aggregates in anti\u2013PD-1\/PD-L1 gastritis. Duodenal biopsies from patients on CPIs revealed chronic duodenitis with villous blunting, mimicking celiac disease. Compared with celiac disease, CPI duodenitis demonstrated higher prevalence of neutrophilic infiltrates and erosions, increased lamina propria CD3 and CD8 T cells, and reduced CD4:CD8 ratio. Upper gastrointestinal biopsies were more inflamed than concomitant colonic biopsies in the majority of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>The morphologic and immunophenotypic distinctions between CPI-associated upper gastrointestinal injuries and common infectious and autoimmune diseases may provide useful discriminators when clinicians are confronted with gastric and duodenal inflammatory changes in patients receiving CPI therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2019-0700-oa","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T15:57:11Z","timestamp":1594051031000},"page":"191-200","source":"Crossref","is-referenced-by-count":40,"title":["Immune Checkpoint Inhibitor\u2013Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From,\n                    <i>Helicobacter pylori<\/i>\n                    Gastritis and Celiac Disease"],"prefix":"10.5858","volume":"145","author":[{"given":"Lina","family":"Irshaid","sequence":"first","affiliation":[{"name":"From the Department of Pathology, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie E.","family":"Robert","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuchen","family":"Zhang","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Yale University School of Medicine, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"2021012621544288900_i1543-2165-145-2-191-b01","doi-asserted-by":"crossref","unstructured":"Havel\n              JJ,\n            \n            \n              Chowell\n              D,\n            \n            \n              Chan\n              TA.\n            \n          \n          The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.\n\t\t\t\t\tNat Rev Cancer.\n\t\t\t\t\t2019;\n\t\t\t\t\t19(3):\n\t\t\t\t\t133\u2013\n\t\t\t\t\t150.","DOI":"10.1038\/s41568-019-0116-x"},{"key":"2021012621544288900_i1543-2165-145-2-191-b02","doi-asserted-by":"crossref","unstructured":"Darvin\n              P,\n            \n            \n              Toor\n              SM,\n            \n            \n              Sasidharan Nair\n              V,\n            \n            \n              Elkord\n              E.\n            \n          \n          Immune checkpoint inhibitors: recent progress and potential biomarkers.\n\t\t\t\t\tExp Mol Med.\n\t\t\t\t\t2018;\n\t\t\t\t\t50(12):\n\t\t\t\t\t165.","DOI":"10.1038\/s12276-018-0191-1"},{"key":"2021012621544288900_i1543-2165-145-2-191-b03","doi-asserted-by":"crossref","unstructured":"Gong\n              J,\n            \n            \n              Chehrazi-Raffle\n              A,\n            \n            \n              Reddi\n              S,\n            \n            \n              Salgia\n              R.\n            \n          \n          Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.\n\t\t\t\t\tJ Immunother Cancer.\n\t\t\t\t\t2018;\n\t\t\t\t\t6(1):\n\t\t\t\t\t8.","DOI":"10.1186\/s40425-018-0316-z"},{"key":"2021012621544288900_i1543-2165-145-2-191-b04","doi-asserted-by":"crossref","unstructured":"Hargadon\n              KM,\n            \n            \n              Johnson\n              CE,\n            \n            \n              Williams\n              CJ.\n            \n          \n          Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors.\n\t\t\t\t\tInt Immunopharmacol.\n\t\t\t\t\t2018;\n\t\t\t\t\t62:\n\t\t\t\t\t29\u2013\n\t\t\t\t\t39.","DOI":"10.1016\/j.intimp.2018.06.001"},{"key":"2021012621544288900_i1543-2165-145-2-191-b05","doi-asserted-by":"crossref","unstructured":"Sandigursky\n              S,\n            \n            \n              Mor\n              A.\n            \n          \n          Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.\n\t\t\t\t\tCurr Rheumatol Rep.\n\t\t\t\t\t2018;\n\t\t\t\t\t20(10):\n\t\t\t\t\t65.","DOI":"10.1007\/s11926-018-0770-0"},{"key":"2021012621544288900_i1543-2165-145-2-191-b06","doi-asserted-by":"crossref","unstructured":"Martins\n              F,\n            \n            \n              Sofiya\n              L,\n            \n            \n              Sykiotis\n              GP,\n            \n            et al.\n          \n          Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.\n\t\t\t\t\tNat Rev Clin Oncol.\n\t\t\t\t\t2019;\n\t\t\t\t\t16(9):\n\t\t\t\t\t563\u2013\n\t\t\t\t\t580.","DOI":"10.1038\/s41571-019-0218-0"},{"key":"2021012621544288900_i1543-2165-145-2-191-b07","doi-asserted-by":"crossref","unstructured":"Teufel\n              A,\n            \n            \n              Zhan\n              T,\n            \n            \n              Hartel\n              N,\n            \n            \n              Bornschein\n              J,\n            \n            \n              Ebert\n              MP,\n            \n            \n              Schulte\n              N.\n            \n          \n          Management of immune related adverse events induced by immune checkpoint inhibition.\n\t\t\t\t\tCancer Lett.\n\t\t\t\t\t2019;\n\t\t\t\t\t456:\n\t\t\t\t\t80\u2013\n\t\t\t\t\t87.","DOI":"10.1016\/j.canlet.2019.04.018"},{"key":"2021012621544288900_i1543-2165-145-2-191-b08","doi-asserted-by":"crossref","unstructured":"Jennings\n              JJ,\n            \n            \n              Mandaliya\n              R,\n            \n            \n              Nakshabandi\n              A,\n            \n            \n              Lewis\n              JH.\n            \n          \n          Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies.\n\t\t\t\t\tExpert Opin Drug Metab Toxicol.\n\t\t\t\t\t2019;\n\t\t\t\t\t15(3):\n\t\t\t\t\t231\u2013\n\t\t\t\t\t244.","DOI":"10.1080\/17425255.2019.1574744"},{"key":"2021012621544288900_i1543-2165-145-2-191-b09","doi-asserted-by":"crossref","unstructured":"Zen\n              Y,\n            \n            \n              Chen\n              YY,\n            \n            \n              Jeng\n              YM,\n            \n            \n              Tsai\n              HW,\n            \n            \n              Yeh\n              MM.\n            \n          \n          Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes.\n\t\t\t\t\tHistopathology.\n\t\t\t\t\t2020;\n\t\t\t\t\t76(3):\n\t\t\t\t\t470\u2013\n\t\t\t\t\t480.","DOI":"10.1111\/his.14000"},{"key":"2021012621544288900_i1543-2165-145-2-191-b10","doi-asserted-by":"crossref","unstructured":"Michot\n              JM,\n            \n            \n              Bigenwald\n              C,\n            \n            \n              Champiat\n              S,\n            \n            et al.\n          \n          Immune-related adverse events with immune checkpoint blockade: a comprehensive review.\n\t\t\t\t\tEur J Cancer.\n\t\t\t\t\t2016;\n\t\t\t\t\t54:\n\t\t\t\t\t139\u2013\n\t\t\t\t\t148.","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"2021012621544288900_i1543-2165-145-2-191-b11","doi-asserted-by":"crossref","unstructured":"Som\n              A,\n            \n            \n              Mandaliya\n              R,\n            \n            \n              Alsaadi\n              D,\n            \n            et al.\n          \n          Immune checkpoint inhibitor-induced colitis: a comprehensive review.\n\t\t\t\t\tWorld J Clin Cases.\n\t\t\t\t\t2019;\n\t\t\t\t\t7(4):\n\t\t\t\t\t405\u2013\n\t\t\t\t\t418.","DOI":"10.12998\/wjcc.v7.i4.405"},{"key":"2021012621544288900_i1543-2165-145-2-191-b12","doi-asserted-by":"crossref","unstructured":"de Malet\n              A,\n            \n            \n              Antoni\n              G,\n            \n            \n              Collins\n              M,\n            \n            et al.\n          \n          Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors.\n\t\t\t\t\tEur J Cancer.\n\t\t\t\t\t2019;\n\t\t\t\t\t106:\n\t\t\t\t\t106\u2013\n\t\t\t\t\t114.","DOI":"10.1016\/j.ejca.2018.10.006"},{"key":"2021012621544288900_i1543-2165-145-2-191-b13","doi-asserted-by":"crossref","unstructured":"Soularue\n              E,\n            \n            \n              Lepage\n              P,\n            \n            \n              Colombel\n              JF,\n            \n            et al.\n          \n          Enterocolitis due to immune checkpoint inhibitors: a systematic review.\n\t\t\t\t\tGut.\n\t\t\t\t\t2018;\n\t\t\t\t\t67(11):\n\t\t\t\t\t2056\u2013\n\t\t\t\t\t2067.","DOI":"10.1136\/gutjnl-2018-316948"},{"key":"2021012621544288900_i1543-2165-145-2-191-b14","doi-asserted-by":"crossref","unstructured":"Samaan\n              MA,\n            \n            \n              Pavlidis\n              P,\n            \n            \n              Papa\n              S,\n            \n            \n              Powell\n              N,\n            \n            \n              Irving\n              PM.\n            \n          \n          Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management.\n\t\t\t\t\tNat Rev Gastroenterol Hepatol.\n\t\t\t\t\t2018;\n\t\t\t\t\t15(4):\n\t\t\t\t\t222\u2013\n\t\t\t\t\t234.","DOI":"10.1038\/nrgastro.2018.14"},{"key":"2021012621544288900_i1543-2165-145-2-191-b15","doi-asserted-by":"crossref","unstructured":"Reddy\n              HG,\n            \n            \n              Schneider\n              BJ,\n            \n            \n              Tai\n              AW.\n            \n          \n          Immune checkpoint inhibitor-associated colitis and hepatitis.\n\t\t\t\t\tClin Transl Gastroenterol.\n\t\t\t\t\t2018;\n\t\t\t\t\t9(9):\n\t\t\t\t\t180.","DOI":"10.1038\/s41424-018-0049-9"},{"key":"2021012621544288900_i1543-2165-145-2-191-b16","doi-asserted-by":"crossref","unstructured":"Grover\n              S,\n            \n            \n              Rahma\n              OE,\n            \n            \n              Hashemi\n              N,\n            \n            \n              Lim\n              RM.\n            \n          \n          Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management.\n\t\t\t\t\tAm Soc Clin Oncol Educ Book.\n\t\t\t\t\t2018;\n\t\t\t\t\t38:\n\t\t\t\t\t13\u2013\n\t\t\t\t\t19.","DOI":"10.1200\/EDBK_100013"},{"key":"2021012621544288900_i1543-2165-145-2-191-b17","doi-asserted-by":"crossref","unstructured":"Bamias\n              G,\n            \n            \n              Delladetsima\n              I,\n            \n            \n              Perdiki\n              M,\n            \n            et al.\n          \n          Immunological characteristics of colitis associated with anti-CTLA-4 antibody therapy.\n\t\t\t\t\tCancer Invest.\n\t\t\t\t\t2017;\n\t\t\t\t\t35(7):\n\t\t\t\t\t443\u2013\n\t\t\t\t\t455.","DOI":"10.1080\/07357907.2017.1324032"},{"key":"2021012621544288900_i1543-2165-145-2-191-b18","doi-asserted-by":"crossref","unstructured":"Assarzadegan\n              N,\n            \n            \n              Montgomery\n              E,\n            \n            \n              Anders\n              RA.\n            \n          \n          Immune checkpoint inhibitor colitis: the flip side of the wonder drugs.\n\t\t\t\t\tVirchows Arch.\n\t\t\t\t\t2018;\n\t\t\t\t\t472(1):\n\t\t\t\t\t125\u2013\n\t\t\t\t\t133.","DOI":"10.1007\/s00428-017-2267-z"},{"key":"2021012621544288900_i1543-2165-145-2-191-b19","doi-asserted-by":"crossref","unstructured":"Oble\n              DA,\n            \n            \n              Mino-Kenudson\n              M,\n            \n            \n              Goldsmith\n              J,\n            \n            et al.\n          \n          Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis.\n\t\t\t\t\tAm J Surg Pathol.\n\t\t\t\t\t2008;\n\t\t\t\t\t32(8):\n\t\t\t\t\t1130\u2013\n\t\t\t\t\t1137.","DOI":"10.1097\/PAS.0b013e31817150e3"},{"key":"2021012621544288900_i1543-2165-145-2-191-b20","doi-asserted-by":"crossref","unstructured":"Messmer\n              M,\n            \n            \n              Upreti\n              S,\n            \n            \n              Tarabishy\n              Y,\n            \n            et al.\n          \n          Ipilimumab-induced enteritis without colitis: a new challenge.\n\t\t\t\t\tCase Rep Oncol.\n\t\t\t\t\t2016;\n\t\t\t\t\t9(3):\n\t\t\t\t\t705\u2013\n\t\t\t\t\t713.","DOI":"10.1159\/000452403"},{"key":"2021012621544288900_i1543-2165-145-2-191-b21","doi-asserted-by":"crossref","unstructured":"Nishimura\n              Y,\n            \n            \n              Yasuda\n              M,\n            \n            \n              Ocho\n              K,\n            \n            et al.\n          \n          Severe gastritis after administration of nivolumab and ipilimumab.\n\t\t\t\t\tCase Rep Oncol.\n\t\t\t\t\t2018;\n\t\t\t\t\t11(2):\n\t\t\t\t\t549\u2013\n\t\t\t\t\t556.","DOI":"10.1159\/000491862"},{"key":"2021012621544288900_i1543-2165-145-2-191-b22","doi-asserted-by":"crossref","unstructured":"Gonzalez\n              RS,\n            \n            \n              Salaria\n              SN,\n            \n            \n              Bohannon\n              CD,\n            \n            \n              Huber\n              AR,\n            \n            \n              Feely\n              MM,\n            \n            \n              Shi\n              CJ.\n            \n          \n          PD-1 inhibitor gastroenterocolitis: case series and appraisal of \u201cimmunomodulatory gastroenterocolitis.\u201d\n          \n            Histopathology\n          .\n\t\t\t\t\t2017;\n\t\t\t\t\t70(4):\n\t\t\t\t\t558\u2013\n\t\t\t\t\t567.","DOI":"10.1111\/his.13118"},{"key":"2021012621544288900_i1543-2165-145-2-191-b23","doi-asserted-by":"crossref","unstructured":"Zhang\n              ML,\n            \n            \n              Neyaz\n              A,\n            \n            \n              Patil\n              D,\n            \n            \n              Chen\n              J,\n            \n            \n              Dougan\n              M,\n            \n            \n              Deshpande\n              V.\n            \n          \n          Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies.\n\t\t\t\t\tHistopathology.\n\t\t\t\t\t2020;\n\t\t\t\t\t76(2):\n\t\t\t\t\t233\u2013\n\t\t\t\t\t243.","DOI":"10.1111\/his.13963"},{"key":"2021012621544288900_i1543-2165-145-2-191-b24","doi-asserted-by":"crossref","unstructured":"Gentile\n              NM,\n            \n            \n              D'Souza\n              A,\n            \n            \n              Fujii\n              LL,\n            \n            \n              Wu\n              TT,\n            \n            \n              Murray\n              JA.\n            \n          \n          Association Between ipilimumab and celiac disease.\n\t\t\t\t\tMayo Clin Proc.\n\t\t\t\t\t2013;\n\t\t\t\t\t88(4):\n\t\t\t\t\t414\u2013\n\t\t\t\t\t417.","DOI":"10.1016\/j.mayocp.2013.01.015"},{"key":"2021012621544288900_i1543-2165-145-2-191-b25","doi-asserted-by":"crossref","unstructured":"Ross\n              WA,\n            \n            \n              Ghosh\n              S,\n            \n            \n              Dekovich\n              AA,\n            \n            et al.\n          \n          Endoscopic biopsy diagnosis of acute gastrointestinal graft-versus-host disease: rectosigmoid biopsies are more sensitive than upper gastrointestinal biopsies.\n\t\t\t\t\tAm J Gastroenterol.\n\t\t\t\t\t2008;\n\t\t\t\t\t103(4):\n\t\t\t\t\t982\u2013\n\t\t\t\t\t989.","DOI":"10.1111\/j.1572-0241.2007.01639.x"},{"key":"2021012621544288900_i1543-2165-145-2-191-b26","doi-asserted-by":"crossref","unstructured":"Aslanian\n              H,\n            \n            \n              Chander\n              B,\n            \n            \n              Robert\n              M,\n            \n            et al.\n          \n          Prospective evaluation of acute graft-versus-host disease.\n\t\t\t\t\tDig Dis Sci.\n\t\t\t\t\t2012;\n\t\t\t\t\t57(3):\n\t\t\t\t\t720\u2013\n\t\t\t\t\t725.","DOI":"10.1007\/s10620-011-1938-x"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/145\/2\/191\/2715932\/i1543-2165-145-2-191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/145\/2\/191\/2715932\/i1543-2165-145-2-191.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:40:51Z","timestamp":1764790851000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/145\/2\/article-p191.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,7,6]]},"published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2019-0700-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,6]]}}}